

Packaging Insert of Bivalent Poliomyelitis Vaccine Type 1 & Type 3, Live (Oral)

Bulk source: PT. Biofarma, Indonesia.

Note : The pictures of VVM & Diagrams for vaccine delivery shall also be printed in the colour as of text.

Size : 95x245mm (Front)

Size : 95x245mm (Back)

Bivalent Poliomyelitis Vaccine Type 1 & Type 3, Live (Oral)

GENERIC NAME

The Bivalent Poliomyelitis Vaccine Type 1 & Type 3, Live (Oral) (bOPV) contains suspensions of live attenuated Poliomyelitis type 1 & type 3 viruses (Sabin strains) propagated in Monkey kidney cells. Bivalent Poliomyelitis Vaccine Type 1 & Type 3, Live (Oral) complies with WHO recommendations.

QUALITATIVE AND QUANTITATIVE COMPOSITION

Each dose of 2 drops (0.1 ml) contains
Polio virus (Sabin), grown on Monkey kidney cells
Type 1 Not Less Than $10^{6.0}$ CCID₅₀
Type 3 Not Less Than $10^{6.0}$ CCID₅₀
Kanamycin Acid Sulphate not more than 20 µg
Neomycin Sulphate not more than 20 µg
Stabilizer: 1 M MgCl₂
Phenol Red: Traces amount

DOSAGE FORM AND STRENGTH

Oral suspension

The vaccine is presented as clear liquid, light reddish colored suspension for oral administration

CLINICAL PARTICULARS

Clinical Studies:

There were 3 clinical studies conducted on bOPV (Bulk PT BioFarma)

1. Phase I Study Protocol No. RPC273:

In randomized, controlled, 5-arm, comparative study in 900 new born to evaluate the immunogenicity and reactivity of Trivalent Oral Polio Vaccine (iOPV) versus 2 Oral Polio Vaccine (mOPV2) & Monovalent Type 3 Oral Polio Vaccine (mOPV3); and Bivalent Oral Polio Vaccine (bOPV) versus Monovalent Type 1 Oral Polio Vaccine (mOPV1) & Monovalent Type 3 Oral Polio Vaccine (mOPV3). The seroconversion rate for Type 1 Polio virus and Type 3 Polio virus with bOPV was 80.3% and 70.9% respectively. Results were comparable to the seroconversion achieved with mOPV1 vaccine for Polio virus Type 1 and with mOPV3 vaccine for Type 3 Polio virus. There were 19 SAEs occurred in the study which were unrelated to study vaccine.

2. Phase III Study Protocol No. PBL/CR/2010/02/CT:

In comparative phase III clinical trial, immunogenicity and reactivity of bOPV manufactured from two bulk sources i.e. Sanofi Pasteur, France and PT BioFarma, Indonesia were comparable after administration of single dose to healthy infants of 6 to 10 weeks. The single dose seroconversion rate for Type 1 polio virus was 82.4% and 82.9% and for type 3 polio virus was 80.8% and 77.5% for bOPV (Sanofi) and bOPV (PT BioFarma) respectively. There was one SAE sepsis with acute gastroenteritis with diselectrolytemia with paralytic ileus which was not causally linked to the vaccine. There were no AEs reported related to bOPV.

3. Phase IV Study Protocol No. PBL/CR/2011/02/CT:

In clinical study to assess the mucosal immunity to Polioviruses after a supplemental dose of bOPV or IPV in 990 children in northern India, seroconversions induced to Poliovirus type 1 at day 28 after the administration of a bOPV dose were 14.3%, 12.9%, and 42.4% for subjects in 6 to 11 month, 5-years, and 10 years age groups, respectively. Seroconversions induced to Poliovirus type 3 at day 28 after the administration of a bOPV dose were 14.1%, 15.9%, and 53.5% for subjects in 6 to 11 month, 5-years, and 10 years age groups respectively. There were no AEs related to study vaccine.

Immunogenicity results of clinical studies do not demonstrate interference by co-administered EPI vaccines.

4. Periodic Safety Updated Report (PSUR Data):

During the reporting period from 2009 to till date, there were total 24 unlisted adverse reaction (07 Gastroenteritis, 01 Anemia, 01 Anal abscess, 01 Sepsis neonatal, 01 Abdominal distension, 02 Diarrhea, 01 Ileus paralytic, 01 Vomiting, 01 Pyrexia, 01 Blood electrolyte abnormal, 02 Dehydration, 01 Malnutrition, 01 Asthma, 01 Pneumonitis, 02 Wheezing) reported and out of these 10 were reported from clinical studies which were unrelated to bOPV. 2 serious listed ADR of VAPP (Vaccine associated Paralytic Polio) reported from literature which was related to bOPV.

Geographical exposure:

In addition to India, bOPV was extensively used in the countries of Asian and African region.

Therapeutic Indication

Bivalent Oral Poliomyelitis Vaccine Type 1 & 3 is indicated for active immunization against infections caused by Type 1 and 3 poliomyelitis viruses.

Posology and method of administration

Vaccination must be in accordance with national or WHO recommendations.

In a multidose container, one dose of 0.1 ml is contained in two drops

IMMUNIZATION SCHEDULE

Bivalent Oral Poliomyelitis Vaccine Type 1 & 3, is indicated for routine immunization against Poliomyelitis at birth and at 6, 10, 14 weeks or 2, 3 and 4 months and supplementary immunization activities (SIAs) in all age groups. The advised vaccination schedule for each country must be in accordance with the national or WHO recommendations.

In addition to bOPV routine immunization, one dose of IPV at 14 weeks is recommended to provide protection against Polio virus type 2 as risk mitigation.

According to WHO recommendations, Bivalent Oral Poliomyelitis Vaccine Type 1 & 3, can be administered at the same time with Measles, Mumps, Rubella, DTP, DT, TT, Td, BCG, Hepatitis B, *Haemophilus influenzae* type b and Yellow Fever vaccines and vitamin supplementation.

ADMINISTRATION

Vaccines should be inspected visually for any particulate matter prior to administration.

Bivalent Oral Poliomyelitis Vaccine Type 1 & 3, must be administered orally. Two drops are delivered directly into the mouth of vaccinees from the multi-dose vial or dropper. For older children it may be preferred to avoid the possible bitter taste by first placing the drops on a sugar lump or in syrup. Care should be taken not to contaminate a multidose dropper with saliva of the vaccinee. Once opened, multi-dose vials should be kept between +2°C and +8°C.

Multi-dose vials of Bivalent Oral Poliomyelitis Vaccine Type 1 & 3, Live from which one or more doses of vaccine have been removed during an immunization session may be used in subsequent immunization sessions, for up to a maximum of 28 days provided that all of the following conditions are met (as described in the WHO policy statement: Handling of multi dose vaccine vials after opening, WHO/IVB/14.07).

- The vaccine is currently prequalified by WHO;
- The vaccine is approved for use for up to 28 days after opening the vial, as determined by WHO;
- The expiry date of the vaccine has not passed;
- The vaccine vial has been, and will continue to be, stored at WHO - or manufacturer recommended temperatures; furthermore, the vaccine vial monitor, if one is attached, is visible on the vaccine label and is not past its discard point, and the vaccine has not been damaged by freezing.

After opening, immediate use is recommended.

When distribution or administration is not imminent, it is advisable to store the vaccine, if possible, at temperatures of -20°C or lower since this halts deterioration. If the vaccine has been stored accidentally at high temperature or generalized malignancy, it is recommended that the vaccine be used immediately or stored ideally at -20°C or at 2-8°C until administration under condition that the VVM allows its use.

CONTRAINDICATIONS

Bivalent Poliomyelitis Vaccine Type 1 & Type 3, Live (Oral) is contraindicated in subjects with known hypersensitivity to neomycin or kanamycin, or to any other component of the vaccine.

In case of diarrhoea or vomiting (including gastrointestinal infection), the dose received will not be counted as part of the immunization schedule and it should be postponed in subjects suffering from acute severe febrile illness, or persistent diarrhoea or vomiting. However, the presence of a minor infection, such as a cold, should not result in the deferral of vaccination. The attenuated poliomyelitis viruses multiply in the gut. The faecal excretion of the vaccine viruses may persist for several weeks and may also be transmitted to the contacts of the vaccinees; contacts of vaccinees should therefore be warned about the need for strict personal hygiene.

Non-immune persons in close contact with a recently vaccinated subject may very rarely be at risk of vaccine-associated paralytic poliomyelitis.

Whenever Bivalent Poliomyelitis Vaccine Type 1 & Type 3, Live (Oral) is administered to an individual, it is good clinical practice to offer immunization to susceptible close contacts (such as unvaccinated parents) at the same time.

Concomitant Vaccines

According to WHO recommendations, Bivalent Oral Poliomyelitis Vaccine Type 1 & 3, can be administered at the same time with Measles, Mumps, Rubella, DTP, DT, TT, Td, BCG, Hepatitis B, *Haemophilus influenzae* type b and Yellow Fever vaccines and vitamin supplementation.

Immune Deficiency

Bivalent Poliomyelitis Vaccine Type 1 & Type 3, Live (Oral) is contraindicated in subjects suffering from primary and secondary immunodeficiency's including medication, leukaemia, lymphoma or generalized malignancy.

For those persons it is recommended to use an inactivated Polio vaccine (IPV). However, according to the WHO Expanded Programme on Immunization (EPI) recommendations symptomatic and asymptomatic infection with human immunodeficiency virus is not a contraindication for immunization with Bivalent Poliomyelitis Vaccine Type 1 & Type 3, Live (Oral).

Use in special populations (such as pregnant women, lactating women, paediatric patients, geriatric patients etc.)

Bivalent Poliomyelitis Vaccine Type 1 & Type 3, Live (Oral) should under no circumstances be injected. It may not prevent or modify the course of the disease in subjects already infected with a wild Type 1 or 3 Poliomyelitis virus. The administration of Bivalent Poliomyelitis Vaccine Type 1 & 3, Live (Oral) should be postponed in subjects suffering from acute severe febrile illness, or persistent diarrhoea or vomiting. However, the presence of a minor infection, such as a cold, should not result in the deferral of vaccination. The attenuated poliomyelitis viruses multiply in the gut. The faecal excretion of the vaccine viruses may persist for several weeks and may also be transmitted to the contacts of the vaccinees; contacts of vaccinees should therefore be warned about the need for strict personal hygiene.

Non-immune persons in close contact with a recently vaccinated subject may very rarely be at risk of vaccine-associated paralytic poliomyelitis.

Whenever Bivalent Poliomyelitis Vaccine Type 1 & Type 3, Live (Oral) is administered to an individual, it is good clinical practice to offer immunization to susceptible close contacts (such as unvaccinated parents) at the same time.

As with any vaccine, a protective immune response may not be elicited in all vaccinees. Previous vaccination with IPV is not a contraindication for the use of Bivalent Poliomyelitis Vaccine Type 1 & Type 3, Live (Oral).

Immunosuppressive treatment may reduce the immune response, may favour the multiplication of the vaccine viruses and may increase the length of excretion of the vaccine viruses in the stool. The effect on immunocompromised patients of the administration of Bivalent Poliomyelitis Vaccine Type 1 & Type 3, Live (Oral) has not been evaluated in clinical studies.

Pregnancy

Although there is no evidence that live attenuated polioviruses have adverse effects on the foetus, in accordance with general principles, the vaccine should not be given to pregnant women unless they are exposed to a definite risk of infection with wild

polioviruses. The risk benefit of the use of the vaccine should be evaluated in comparison to the use of inactivated polio vaccines.

Lactation

The effect on breast-fed infants of the administration of Bivalent Poliomyelitis Vaccine Type 1 & Type 3, Live (Oral) to their mothers has not been evaluated in clinical studies. No known contra-indication has been established. The vaccine may be administered to a lactating mother.

Women of childbearing potential contraception

Non-immune women of child-bearing age should use contraception during 3 months following vaccination.

Effects on ability to drive and use machines

There have been no studies to investigate the effect of Bivalent Poliomyelitis Vaccine Type 1 & Type 3, Live (Oral) on driving performance or the ability to operate machinery.

Undesirable effects

In the vast majority of cases there are no undesirable effects. Very rarely, there may be vaccine associated paralysis (one case per one million doses administered). Persons in close contact with a recently vaccinated child may very rarely be at risk of vaccine associated paralytic Poliomyelitis.

Overdose

No reports of overdose with Panacea Biotec's Bivalent Poliomyelitis Vaccine Type 1 & Type 3, Live (Oral) have been received.

PHARMACOLOGICAL PROPERTIES

Mechanism of action

Bivalent Oral Poliomyelitis Vaccine Type 1 & 3, elicits immune response by producing neutralizing antibodies against polio virus type 1 and 3

Pharmacodynamics properties

On the basis of clinical study and published literature, it can be estimated that the seroresponse against Types 1 and 3 Poliomyelitis viruses will be at least equal to those obtained with a trivalent oral Poliomyelitis vaccine (tOPV).

Pharmacokinetic properties

Evaluation of pharmacokinetics is not required for vaccines.

Nonclinical properties

Animal Toxicology or Pharmacology

As the safety of OPV variants has been proven through its extensive usage over the years, no separate pre-clinical study was performed for Bivalent Oral Poliomyelitis Vaccine Type 1 & 3.

Description

The Bivalent Poliomyelitis Vaccine Type 1 & Type 3, Live (Oral) (bOPV) contains suspensions of live attenuated Poliomyelitis type 1 & type 3 viruses (Sabin strains) propagated in Monkey kidney cells. Bivalent Poliomyelitis Vaccine Type 1 & Type 3, Live (Oral) complies with WHO recommendations.

Pharmaceutical particulars

Incompatibilities

This biological product must not be mixed with other biological products.

Shelf Life

Assigned shelf life is 24 months when stored at minus 20°C.

Packaging information

Nature and contents of container: Glass Vials

They are colorless, transparent glass free from any tinge and visual defect made from USP Type-1 glass.

Rubber Stopper: Grey bromobutyl Rubber Stoppers, they are homogenous and practically free from flash and adventitious material such as fibers, foreign particles and adhering rubber pieces.

Aluminium Seal: 1.3mm plain circular aluminium seal with lacquered finish made of virgin material and free from foreign particles.


Storage

Vaccine is potent if stored at not higher than -20° C until the expiry date indicated on the vial. It can be stored for upto six months between +2° C and +8° C.

Presentation:

The vaccine comes in vials of 20 doses and 10 doses.

Vaccine Vial Monitors (VVMs) are part of the label on all Bivalent Poliomyelitis Vaccine Type 1 & Type 3, Live (Oral) vaccine vials. These VVMs are supplied by TEMPTIME Corporation, U.S.A. The colour dot which appears on the label of the vial is a VVM. This is a time-temperature sensitive dot that provides an indication of the cumulative heat to which the vial has been exposed. It warns the end user when exposure to heat is likely to have degraded the vaccine beyond an acceptable level. The interpretation of the VVM is simple. "Focus on the central square". Its colour will change progressively on exposure to high temperature. As long as the colour of this square is lighter than the colour of the outer circle the vaccine can be used. As soon as the colour of the central square is the same colour as the outer circle or of a darker colour than the outer circle, the vaccine vial should be discarded.



Directions for use of droppers

- Use specific droppers supplied by Panacea Biotec Ltd.
- Dropper should be discarded with vaccine vial as re-use of droppers from one vial to another may lead to crack and leakage.
- Always hold the vial in tilted position (ref. Fig. as below) for vaccine delivery.
- Press the dropper gently just above the delivery nozzle with soft part of the fingers avoiding nail contact.
- Bring vial along with dropper back to upright position after delivery of each dose.
- Put the nozzle cover back on the dropper when there is some time elapsed between two consecutive vaccine deliveries.



Hold the vial at tilted position
during vaccine delivery into the mouth



Do not hold the vial horizontally
for vaccine delivery into the mouth



Do not hold the vial vertically
for vaccine delivery into the mouth

Patient Counseling Information

Provide the following information to the parent or guardian:

- Inform of the potential benefits and risks of immunization with bOPV.
- Inform about the potential for adverse reactions that have been temporally associated with administration of bOPV or other vaccines containing similar components.
- Give the Prescribing Information, which is required by the NDCT Rules 2019 to be given prior to immunization. These materials are available free of charge at the Central Drugs Standard Control Organization website (<https://cdscg.gov.in/opencms/opencms/en/biologicals/Vaccines>)

Details of Manufacturer:

Manufactured by: **Panacea Biotec Ltd.**
Malpur, Baddi, Distt. Solan (H.P.) - 173 205, India.

Details of permission or licence number with date:

License Number: MB/07/632 dated 01.06.2017

Date of revision: September 2023

Bulk source: PT. Biofarma, Indonesia.

Panacea Biotec
Innovation in support of life

PMP/IS/0706